-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
-
-
-
-
-
-
-
RBC Capital on Bristol-Myers Squibb's (BMY) AZN Deal Feedback
-
-
-
-
-
-
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $75 at Guggenheim
-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) Declares $0.63 Quarterly Dividend; 4.6% Yield
-
-
-
-
-
-
-
Bristol Myers Squibb drug reduces multiple myeloma progression risk by 52%
-
-
-
-
-
-
-
Bristol Myers Squibb gets EU approval for Sotyktu to treat psoriatic arthritis
-
-
-
-
-
-
-
Raymond James Preview Bristol-Myers Squibb Co. (BMY) Earnings: 'Our updated diluted non-GAAP EPS is $1.49 for 1Q26 '
-
464,586 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

